We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America
News

ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America

ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America
News

ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ReachBio LLC has announced that it will distribute the full product line of Axiogenesis AG to the North American life science research and drug discovery market.

Axiogenesis’ products consist of highly pure and well-characterized tissue-specific cells derived from specially engineered mouse embryonic stem cell lines. Major applications for the cells include drug discovery, toxicity testing of new drug candidates and other compounds, and basic research.

The first cell types available from Axiogenesis are 99.9% pure atrial cardiomyocytes in various formats, including frozen cryovials, pre-seeded 96-well plates, and pre-seeded coverslips.

Branded as Cor.AT cells, these cardiomyocytes have been rigorously functionally qualified and found to be ideal for cardiotoxicity screening, electrophysiology studies, and as a cellular model system for hypertrophic cardiomyopathy. Pure ventricular cardiomyocytes (Cor.VE) are also available.

Advertisement